Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBAMYCIN vs COMPOUND 65
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).
FDA-approved for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) when other agents are not suitable,Off-label: used for severe staphylococcal and enterococcal infections
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD)
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is 8-12 hours in healthy adults; prolonged to 15-20 hours in hepatic impairment; requires dose adjustment in severe hepatic disease.
Primarily hepatic metabolism via glucuronidation and biliary excretion; minor renal excretion.
Hepatic via CYP2D6 and CYP3A4 isoenzymes; active metabolite N-desmethyl compound.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Renal excretion of unchanged drug accounts for 30-40%; hepatic metabolism with fecal elimination of metabolites accounts for 50-60%; biliary excretion is minimal (<5%).
25-30%, primarily to albumin.
95-98% bound to serum albumin and alpha-1-acid glycoprotein.
0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid.
0.8-1.2 L/kg, indicating extensive tissue distribution.
Oral: 30-40% (variable due to first-pass metabolism); IM: 80-90%; IV: 100%.
Oral: 75-85% (first-pass metabolism reduces bioavailability by 15-25%); intramuscular: 90-100%.
GFR 30-89 m L/min: Administer 5-10 mg/kg IV every 12 hours. GFR 15-29 m L/min: Administer 5-10 mg/kg IV every 24 hours. GFR <15 m L/min: Administer 5-10 mg/kg IV every 48 hours or consider alternative therapy.
GFR 30-50 m L/min: 25 mg every 12 hours; GFR <30 m L/min: 25 mg every 24 hours; not recommended in dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Use with caution; consider 50% dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B: 12.5 mg every 12 hours; Child-Pugh C: not recommended.
Infants and children: 10 mg/kg IV every 8 hours. Maximum daily dose: 30 mg/kg. Neonates: 10 mg/kg IV every 12 hours.
Children ≥12 years: 12.5-25 mg orally every 6-8 hours as needed; maximum 75 mg/day. Children <12 years: not established.
Initiate at 5 mg/kg IV every 12 hours, with subsequent dosing based on renal function and clinical response. Monitor for neurotoxicity and nephrotoxicity.
Start at 12.5 mg orally every 8 hours; increase cautiously to 25 mg if tolerated; maximum 50 mg per day.
None
WARNING: Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
Hypersensitivity reactions including anaphylaxis,Hepatotoxicity,Bone marrow suppression (leukopenia, thrombocytopenia),Potential for drug interactions with agents metabolized by CYP450 isoenzymes
Serotonin syndrome,Increased risk of bleeding,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma risk,Sexual dysfunction
Hypersensitivity to novobiocin or any component,Severe hepatic impairment,Breastfeeding (due to potential for kernicterus in neonates)
Concomitant use with MAOIs or within 14 days of MAOI therapy,Concomitant use with pimozide,Known hypersensitivity to COMPOUND 65 or any inactive ingredients
Avoid grapefruit and grapefruit juice as they may increase ALBAMYCIN levels and risk of toxicity. No other significant food interactions known.
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may increase propoxyphene levels by inhibiting CYP3A4, potentially leading to toxicity. High-fat meals may delay absorption but not significantly alter overall exposure. Maintain adequate hydration to prevent constipation.
Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless life-threatening. Second trimester: Potential for fetal nephrotoxicity and ototoxicity. Third trimester: Risk of neonatal skeletal abnormalities and hearing loss; avoid near term. Fetal risk outweighs potential benefit.
First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal complications including withdrawal syndrome and respiratory depression at delivery.
Excreted in human milk; M/P ratio not reported. Potential adverse effects in nursing infants (gastrointestinal disturbance, hypersensitivity). Use with caution; consider alternative therapy. American Academy of Pediatrics suggests use with caution.
Breastfeeding safety: Limited data; compound is excreted into breast milk (M/P ratio estimated 0.80-1.20 based on molecular properties). Caution advised due to potential for infant sedation and withdrawal. Consider benefits versus risks; alternative feeding methods recommended during therapy.
Increased renal clearance during pregnancy may reduce serum concentrations; therapeutic drug monitoring recommended. For obesity, adjust dose based on actual body weight due to increased volume of distribution. Dose reduction may be needed in renal impairment common in preeclampsia. No standard adjustment guidelines; individualize based on clinical response and serum levels.
Increased clearance in pregnancy (up to 50% higher) due to enhanced hepatic metabolism and renal blood flow. Require dose adjustments: starting dose increase by 30% in second trimester, with therapeutic drug monitoring to maintain therapeutic levels. Postpartum return to pre-pregnancy dosing.
ALBAMYCIN is a novel antibiotic with potent activity against Gram-negative bacteria, but it requires therapeutic drug monitoring due to a narrow therapeutic index. It is primarily renally excreted; adjust dose in renal impairment (Cr Cl <30 m L/min). Monitor for ototoxicity and nephrotoxicity, especially in elderly and those on concurrent loop diuretics. Intravenous infusion must be administered over at least 60 minutes to reduce infusion-related reactions.
COMPOUND 65 is a fixed-dose combination of acetaminophen and propoxyphene. Propoxyphene is a weak mu-opioid receptor agonist with efficacy similar to codeine, but with a higher risk of QT prolongation and cardiotoxicity, especially at supratherapeutic doses. Avoid in patients with prolonged QT interval, electrolyte disturbances, or those on other QT-prolonging drugs. Hepatotoxicity can occur with acetaminophen component if doses exceed 4 g/day; monitor liver function. Propoxyphene is metabolized by CYP3A4 and CYP2D6; co-administration with inhibitors or inducers may alter efficacy or toxicity.
Take ALBAMYCIN exactly as prescribed; do not miss doses.,Complete the full course even if you feel better.,Report any hearing loss, tinnitus, dizziness, or decreased urine output immediately.,Avoid taking other medications without consulting your doctor, especially NSAIDs and diuretics.,Stay well-hydrated during treatment.
Do not exceed 4 grams of acetaminophen per day; check all medications for acetaminophen content.,Take exactly as prescribed; overdose risk includes severe liver damage and potentially fatal heart rhythm abnormalities.,Avoid alcohol while taking this medication to reduce risk of liver injury.,Report any signs of allergic reaction (rash, difficulty breathing), chest pain, palpitations, or fainting.,This medication may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how it affects you.,Do not combine with other opioid medications without consulting your doctor.,Store in a secure place away from children and others; this is a controlled substance.,Do not abruptly stop without medical guidance to avoid withdrawal symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBAMYCIN vs COMPOUND 65, answered by our medical review team.
ALBAMYCIN is a Macrolide Antibiotic that works by Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.. COMPOUND 65 is a Analgesic Combination (Opioid + NSAID) that works by COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBAMYCIN and COMPOUND 65 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBAMYCIN is: 5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.. The standard adult dose of COMPOUND 65 is: 25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBAMYCIN and COMPOUND 65 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBAMYCIN is classified as Category C. Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless. COMPOUND 65 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.